Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability
Ziva D Cooper, Gillinder Bedi, Divya Ramesh, Rebecca Balter, Sandra D Comer, Margaret Haney
Neuropsychopharmacology | NATURE PUBLISHING GROUP | Published : 2018
Awarded by US National Institute on Drug Abuse
This research was supported by US National Institute on Drug Abuse Grant DA19239, DA009236, and DA027755. ZDC, GB, DR, RB, SDC, and MH have no competing interests in relation to the work described. ZDC and MH have received research funds and partial salary support from Insys Therapuetics. Over the past 3 years, SDC received compensation (in the form of partial salary support) from studies supported by Braeburn Pharmaceuticals, Cerecor, Indivior, MediciNova, and Reckitt-Benckiser Pharmaceuticals. In addition, SDC has served as a consultant to the following companies over the past 3 years: Advances in Pain Management, AstraZeneca, Clinilabs, Collegium Pharmaceutical, Daiichi Sankyo, Depomed, Egalet, Endo, Guide point Global, Heptares Therapeutics Limited, Inspirion Delivery Sciences, IntelliPharma-Ceutics, Janssen, KemPharm, Mallinckrodt, Neuromed, Opiant, Orexo, Pfizer, and Shire.